Twitter Adopting a ‘Poisoned Pill’ Strategy to Fight Elon Musk Takover

Twitter has announced it is fighting back against Elon Musk's hostile takeover attempt, adopting a "poisoned pill" strategy....
Twitter Adopting a ‘Poisoned Pill’ Strategy to Fight Elon Musk Takover
Written by Matt Milano

Twitter has announced it is fighting back against Elon Musk’s hostile takeover attempt, adopting a “poisoned pill” strategy.

Elon Musk made an unsolicited bid to purchase Twitter for $54.20 a share. Since making the offer, Musk has indicated his desire to take Twitter private if the deal goes through, but Twitter’s board is not interested.

The company has announced it is enacting “a limited duration shareholder rights plan (the ‘Rights Plan’)” to fight Musk’s takeover attempt. Under the plan, if any one shareholder gains a 15% or greater stake in the company, more shares would become available for all other shareholders to purchase at a discounted price. This would dilute Musk’s stake in the company, and allow other shareholders to effectively counter Musk by making it prohibitively expensive for him to purchase more than 15% of the company.

“The Rights Plan is intended to enable all shareholders to realize the full value of their investment in Twitter,” the company writes. “The Rights Plan will reduce the likelihood that any entity, person or group gains control of Twitter through open market accumulation without paying all shareholders an appropriate control premium or without providing the Board sufficient time to make informed judgments and take actions that are in the best interests of shareholders.”

While Elon Musk may be the richest man in the world, Twitter’s poisoned pill may make the takeover too expensive even for him.

Subscribe for Updates

CEOTrends Newsletter

CEO related news and updates.

By signing up for our newsletter you agree to receive content related to ientry.com / webpronews.com and our affiliate partners. For additional information refer to our terms of service.
Get the WebProNews newsletter delivered to your inbox

Get the free daily newsletter read by decision makers

Subscribe
Advertise with Us

Ready to get started?

Get our media kit

Advertise with Us